Phase I Pediatric FMP2.1/AS02A Trial in Mali

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Plasmodium Falciparum Malaria
Interventions
BIOLOGICAL

FMP2.1/AS02A

FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.

BIOLOGICAL

Rabies vaccine (RabAvert)

RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.

Trial Locations (1)

Unknown

University of Bamako, Malaria Research and Training Center, Bamako

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Walter Reed Army Institute of Research (WRAIR)

FED

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

University of Maryland, Baltimore

OTHER

lead

U.S. Army Medical Research and Development Command

FED

NCT00358332 - Phase I Pediatric FMP2.1/AS02A Trial in Mali | Biotech Hunter | Biotech Hunter